EARNEST Partners’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-178
Closed -$90.1K 1006
2023
Q3
$90.1K Hold
178
﹤0.01% 325
2023
Q2
$92.9K Hold
178
﹤0.01% 312
2023
Q1
$103K Hold
178
﹤0.01% 300
2022
Q4
$98K Hold
178
﹤0.01% 300
2022
Q3
$90K Hold
178
﹤0.01% 291
2022
Q2
$97K Hold
178
﹤0.01% 289
2022
Q1
$105K Hold
178
﹤0.01% 288
2021
Q4
$119K Sell
178
-21
-11% -$13.1K ﹤0.01% 282
2021
Q3
$114K Hold
199
﹤0.01% 273
2021
Q2
$100K Hold
199
﹤0.01% 279
2021
Q1
$91K Hold
199
﹤0.01% 283
2020
Q4
$93K Hold
199
﹤0.01% 277
2020
Q3
$88K Hold
199
﹤0.01% 270
2020
Q2
$72K Hold
199
﹤0.01% 280
2020
Q1
$56K Hold
199
﹤0.01% 288
2019
Q4
$65K Hold
199
﹤0.01% 293
2019
Q3
$58K Hold
199
﹤0.01% 299
2019
Q2
$58K Hold
199
﹤0.01% 302
2019
Q1
$54K Hold
199
﹤0.01% 307
2018
Q4
$45K Hold
199
﹤0.01% 311
2018
Q3
$49K Hold
199
﹤0.01% 321
2018
Q2
$41K Hold
199
﹤0.01% 335
2018
Q1
$41K Hold
199
﹤0.01% 333
2017
Q4
$38K Buy
+199
New +$38.1K ﹤0.01% 333
2017
Q1
Sell
-199
Closed -$28K 834
2016
Q4
$28K Buy
+199
New +$29.3K ﹤0.01% 349

Other funds holding TMO

EARNEST Partners's TMO Position: Q4 2023 in Review

EARNEST Partners sold out of Thermo Fisher Scientific (TMO) in Q4 2023, closing a stake of 178 shares — an estimated $90.1K sold.

EARNEST Partners first reported a position in TMO in Q4 2016 and held it in 25 quarters. The position peaked at $119K in Q4 2021. 2,491 funds tracked by Wall St. Rank hold TMO as of Q4 2023.

  • EARNEST Partners reported no remaining Thermo Fisher Scientific position as of Q4 2023 after selling out during the quarter.
  • EARNEST Partners sold 178 Thermo Fisher Scientific shares in Q4 2023, an estimated $90.1K.
  • EARNEST Partners first reported a position in Thermo Fisher Scientific in Q4 2016 and held it in 25 quarters.
  • EARNEST Partners's Thermo Fisher Scientific position peaked at $119K in Q4 2021.
  • 2,491 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q4 2023.

Based on EARNEST Partners's 13F filing for Q4 2023, filed 14 Feb 2024.